Mr. Gilmore previously served as vice president, Strategic Business Ventures at Prasco Laboratories, where he contributed to corporate growth. He has more than 22 years of experience including leadership awards in sales, marketing, business strategy, M&A and global commercialization. During his time at Prasco, he served as a business development consultant for Aprecia, where he successfully established key business partnerships.
"A dedicated steward of a partnering culture, Chris Gilmore is someone who has the ability to spot high potential, build long-term relationships and close deals," said E. Thomas Arington, Aprecia's Chairman. "We are excited to see his enthusiasm and collaborative spirit put to work toward our mission to establish Aprecia as a global leader in new technology platforms that create solutions for unmet healthcare needs."
Aprecia is first and only manufacturer of FDA-approved pharmaceutical products using three dimensional printing (3DP). The company's first technology platform, ZipDose Technology, produces rapidly disintegrating orodispersible tablets designed to address patient compliance by making medicine easy to swallow and administer. In additional to its commercial scalability, 3DP lends itself to small batch production as well, and is prototyping in early drug development and clinical trials. Several different formulations can be achieved within a short period of time enabling the possibility of adaptive clinical trial material. This rapid-prototyping production provides an opportunity to accelerate drug development in both clinical trial and lifecycle extension of pharmaceutical products. Aprecia is currently positioned to expand its 3DP technology across multiple therapeutic categories globally, and has recently signed an agreement with a leading CDMO in Japan as part of this long term strategy.